ABBVie Acquires Apogee Therapeutics for $10.9 Billion

SentiSense · Published · Updated

ABBVie acquired Apogee Therapeutics for $10.9 billion to boost its immunology pipeline, as per multiple reports.

Sign in to read the full story. Free accounts include 20 full reads a month.

Sign in or create a free account

Powered by SentiSense - Intelligent Market Analysis